AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00202852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
Study NCT03094936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: APC
Description: Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
Study NCT03094936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APC
Description: Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
Study NCT03094936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Suture Technique (OverStitch TM)
Description: OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
Study NCT00865254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
Study NCT00865254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Contingency Management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
Study NCT00865254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Enhanced Contingency Management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
Study NCT03869073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
Study NCT03869073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
Study NCT02870452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
Study NCT02870452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
Study NCT01461577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE HOE 901
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02307526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
Study NCT02307526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt table test
Description: After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
Study NCT01675037 — intervention group
Intervention type: OTHER
Intervention: Biological evaluation
Description: Complete hypothalamic-pituitary hormonal evaluation
Study NCT02392871 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Study NCT02392871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (combination)
Description: Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
Study NCT00227877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBA - New England, USA
Description: Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use.
Study NCT00227877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBA - Prague, CZR
Description: Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use.
Study NCT05046210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHA intervention
Description: The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
Study NCT05046210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral exercise intervention
Description: Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
Study NCT05046210 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral exercise intervention
Description: Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
Study NCT03370081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPNOGRAPHY
Description: MONITORING OF CAPNOMETRY USING ETCO2 METHOD
Study NCT02975154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
Study NCT02975154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
Study NCT03662334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Acting insulin with pre-treatment of rHuPH20
Description: Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
Study NCT03662334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection [Camptosar]
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Injection [Camptosar]
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
Study NCT03279510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: Subjects are fit with hearing aids.
Study NCT00894530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
Study NCT00894530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: The 5-FU dosage will remain the standard.
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: The 5-FU dosage will remain the standard.
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: The LV dosage will remain the standard.
Study NCT01523431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: The LV dosage will remain the standard.
Study NCT02042144 — intervention group
Intervention type: DRUG
Intervention: Stivarga (Regorafenib, BAY73-4506)
Description: Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
Study NCT04003389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: administered orally
Study NCT04003389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered orally
Study NCT03228251 — intervention group
Intervention type: OTHER
Intervention: Stroke team simulation training
Description: The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin.
Study NCT00517686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information feedback intervention
Description: This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
Study NCT00707018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External rotation shoulder sling
Description: The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
Study NCT00707018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal rotation shoulder sling
Description: The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
Study NCT01340118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
Study NCT04331769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch Ventricular Restoration System
Description: AccuCinch Ventricular Restoration System
Study NCT04331769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-Directed Medical Therapy
Description: Guideline-Directed Medical Therapy
Study NCT03429907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Exercises
Description: Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
Study NCT03429907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
Study NCT03429907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
Study NCT02295098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter placement
Description: Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
Study NCT02295098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paracostal catheter placement
Description: Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
Study NCT05308485 — intervention group
Intervention type: OTHER
Intervention: Events exposure questionnaire
Description: Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
Study NCT01562015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
Study NCT00005398 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: No applicable
Study NCT01534832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innervision Surgical Smoke Removal System
Description: Smoke removal by electrostatic precipitation
Study NCT01466725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Study NCT01466725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03321929 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Drug: LUM015 Device: LUM 2.6 Imaging Device
Study NCT03576677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min.
Study NCT03576677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group.
Study NCT03311685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal tactile imager
Description: Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
Study NCT03766997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Betamethasone Injection
Description: local injection
Study NCT03766997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: topical use
Study NCT03766997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: topical use
Study NCT03947879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 15 g of L-glutamine twice daily by mouth for 3 months.
Study NCT03947879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No L-glutamine
Description: The same patients will be given no L-glutamine for 3 months.
Study NCT02714205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nitroglycerin
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Study NCT02714205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Study NCT00062738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: Paroxetine CR 12.5 - 25 mg q hs
Study NCT00062738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: nortriptyline 25 - 75 mg q hs
Study NCT00062738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT02277210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flushing
Description: aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
Study NCT02277210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flushing
Description: aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
Study NCT04263922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang granules
Description: Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
Study NCT04263922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan capsule
Description: Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
Study NCT01842464 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Sacro-Spinous
Description: Anterior Sacro-Spinous
Study NCT04222725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed 4 times a day (QID)
Study NCT04222725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed QID
Study NCT04222725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops
Description: Dosed QID
Study NCT02947139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156
Study NCT02947139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20161
Study NCT05286398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatoplasty
Description: Surgical closure of palatal defect
Study NCT05286398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Addition silicone impression
Description: diagnostic impression for maxillary arch